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Abstract
Rationale—Critically ill patients are highly susceptible to hospital-acquired infection. Neutrophil
function in critical illness remains poorly understood.
Objectives—To characterize and define mechanisms of peripheral blood neutrophil (PBN)
dysfunction in critically ill patients. To determine whether the inflamed lung contributes additional
phagocytic impairment.
Methods—Prospective collection of blood and bronchoalveolar lavage fluid from patients with
suspected ventilator-associated pneumonia and from age- and sex-matched volunteers; laboratory
analysis of neutrophil functions.
Measurements and Main Results—Seventy-two patients and 21 volunteers were included.
Phagocytic capacity of PBNs was 36% lower in patients than in volunteers (P < 0.0001). From
several biologically plausible candidates only activated complement was significantly associated
with impaired PBN phagocytosis (P < 0.0001). Phagocytosis was negatively correlated with serum
C3a and positively correlated with expression of C5a receptor type 1 (CD88) on PBNs. C5a
recapitulated impaired PBN phagocytosis and significantly down-regulated CD88 expression in
vitro. C5a-mediated phagocytic impairment was prevented by blocking either CD88 or
phosphoinositide 3-kinase, and completely reversed by granulocyte-macrophage colony-
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stimulating factor. C5a also impaired killing of Pseudomonas aeruginosa by, and migration of,
PBNs, indicating that effects were not restricted to phagocytosis. Bronchoalveolar lavage fluid
leukocytes from patients also demonstrated significantly impaired function, and lavage
supernatant reduced phagocytosis in healthy neutrophils by 43% (P = 0.0001). However, lavage
fluid did not affect CD88 expression and lavage-mediated impairment of phagocytosis was not
blocked by anti-CD88 antibody.
Conclusions—Critically ill patients have significant dysfunction of PBNs, which is mediated
predominantly by activated complement. Further, profound complement-independent neutrophil
dysfunction occurs in the inflamed lung.
Keywords
complement; natural immunity; intensive care; phagocytosis
Patients with critical illness are highly susceptible to developing hospital-acquired infections
(HAIs) (1, 2). HAIs are thought to affect 2 million American patients, resulting in 77,000
additional deaths, per annum (3, 4). Various factors may contribute to the risk of infection
including the nature of the underlying illness (5), medical interventions (e.g., intubation [6],
insertion of vascular lines [7], drugs [8]), and the acquisition and transmission of relatively
virulent pathogens in the intensive care unit (ICU) (9, 10). Running parallel to these themes
is the observation that innate immunity is impaired in critically ill patients. Neutrophils are
critical for the clearance of most ICU-related pathogens, and defective phagocytosis by
peripheral blood neutrophils (PBNs) has been described in mechanically ventilated patients
(11, 12). However, surprisingly little is known about the mechanisms underlying defective
neutrophil function in the critically ill. Identification of such mechanisms would be expected
to suggest novel targets for the prevention and treatment of HAI.
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Neutrophil dysfunction occurs in critical illness but remains poorly characterized. Animal
models of sepsis implicate C5a in this process.
What This Study Adds to the Field
This study provides the first human demonstration of C5a-mediated dysfunction of
peripheral blood neutrophils in critical illness. The findings demonstrate that C5a-
mediated dysfunction of peripheral blood neutrophils is preventable and reversible ex
vivo, suggesting potential therapeutic avenues. Provides evidence that neutrophil
dysfunction persists, but is independent of C5a, in the inflamed lung.
The aims of this study were therefore to characterize neutrophil dysfunction and to define
the underlying mechanism(s) in patients with a high clinical suspicion for ventilator-
associated pneumonia (VAP), the most commonly fatal HAI (13). We hypothesized that
profound systemic inflammation characteristic of critical illness drives impairment of
neutrophil phagocytic capacity. We also sought to determine whether the local, inflamed
environment of the lung imparts additional dysfunction to neutrophils migrating from the
blood. Our work proposes a significant role for activated complement (in particular high
concentrations of C5a) in neutrophil dysfunction in critically ill patients. Elevated
concentrations of C5a have been previously described in sepsis and have been shown to
impair neutrophil function in rodents (14–17). Some of the results of these studies have been
previously reported in the form of an abstract (18).
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METHODS
Reagents
Recombinant human C5a (an anaphylotoxin generated by cleavage of complement factor 5),
formyl methionyl leucyl phenylalanine (fMLP), and platelet-activating factor (PAF) were
from Sigma (Gillingham, UK), and granulocyte-macrophage colony-stimulating factor
(GM-CSF) was from Affinity Bioreagents (Golden, CO). S5/1, a specific antibody against
the C5a receptor CD88, was from Abcam (Cambridge, UK). Fluorophore-labeled antibodies
against CD11b and the Fcγ receptors CD32 and CD64 were obtained from Invitrogen
(Paisley, UK). Isoproterenol (a β1- and β2-adrenoceptor agonist), the adenylate cyclase
inhibitor SQ22536, and the phosphoinositide 3-kinase (PI3K) inhibitors wortmannin and
LY294002 were from Tocris Bioscience (Bristol, UK).
Patients and Volunteers
Patients were recruited from two teaching hospital ICUs if they had clinically suspected
VAP, that is, mechanical ventilation for at least 48 hours, new and persisting infiltrates on a
chest radiograph, and at least two of the following: purulent tracheal secretions, temperature
greater than 38°C, or white cell count greater than 11 × 109/L. Patients provided blood and
had fiberoptic bronchoscopy and bronchoalveolar lavage (BAL) performed by a
standardized technique (see the online supplement for details). This study considered all
patients with clinically suspected VAP together as a single group; however, subgroups with
microbiologically confirmed VAP and adult respiratory distress syndrome are analyzed
separately in the online supplement.
Age- and sex-matched volunteers (MVs) were recruited from a local primary care practice
and also underwent blood sampling, bronchos-copy, and BAL. Exclusion criteria and
additional details pertaining to patients and volunteers are in the online supplement. Separate
university staff and students provided blood to generate healthy PBNs for in vitro
experiments. Informed, witnessed assent was obtained from a relative or main carer for all
patients. Informed, written consent was obtained from all volunteers. The study was
approved by the relevant research ethics committees.
Processing of Bronchoalveolar Lavage Fluid and Blood
Details of processing are in the online supplement. Bronchoalveolar lavage fluid (BALF)
was separated into a cellular fraction and supernatant. Serum and neutrophils were derived
fresh from whole blood (19).
Inflammatory Cytokines and Complement Factors
Concentrations of C3a des-Arg and C5a des-Arg, the breakdown products of complement
factors C3a and C5a, were estimated with a cytometric bead array kit (BD Biosciences,
Oxford, UK). GM-CSF, IL-6, IL-8, and tumor necrosis factor (TNF)-α levels were assessed
by the same method.
Lavage concentrations of these molecules were corrected for dilution by measuring urea in
BALF and plasma (20).
Phagocytosis Assays
PBNs were adhered in Iscove’s modified Dulbecco’s medium (IMDM) containing 10%
autologous serum. Cells were exposed for 1 hour to zymosan particles (Sigma) that had been
preincubated with 50% autologous serum. PBNs were air dried, fixed with methanol, and
stained with Reastain Quik-Diff (Reagena, Toivala, Finland). Light microscopy was used to
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distinguish PBNs containing two or more zymosan particles. Duplicate counts were
performed on four randomly selected fields (minimum of 100 neutrophils per field).
Variations of this core protocol were performed to explore mechanisms underlying defective
phagocytosis, and to assess killing of Pseudomonas aeruginosa strain PA01 (details are in
the online supplement).
Superoxide Production and Transmigration Assays
Neutrophil superoxide production was assayed by cytochrome c reduction assay (21).
Transmigration was quantified by histological assessment of neutrophils traversing a
Transwell filter (pore size, 3 μm; Corning, Lowell, MA). Further details are described in the
online supplement.
Flow Cytometry
PBNs were incubated with primary, fluorophore-tagged antibody or isotype control (details
of labeling and of the antibodies used are in the online supplement). Cells were fixed with
10% formalin and analyzed by FACSCalibur (BD Biosciences). Expression was quantified
as geometric mean fluorescence.
Epithelial Cell Inflammation Assay
A549 cells (American Type Culture Collection, Manassas, VA) (derived from human type II
alveolar epithelial cells [22]) were grown to confluence. Freshly isolated neutrophils
(500,000) were applied. LPS O127:B8 (Sigma), derived from Escherichia coli, was added
(final concentration, 100 ng/ml) for 24 hours at 37°C. To distinguish soluble from
membrane-mediated effects experiments were repeated with permeable membranes
(Transwell; pore size, 0.4 μm), preventing direct contact between neutrophils and A549
cells.
Statistical Analysis
Analysis was conducted with Prism (Graphpad Software, La Jolla, CA). Nonparametric data
were analyzed by the Mann-Whitney U test for two variables and by the Kruskal-Wallis test
for greater than two variables, using Dunn’s post-hoc analysis test. Normally distributed
data were analyzed by Student’s t test or analysis of variance with post-hoc analysis by
Bonferroni’s test. Correlations were assessed by Spearman’s rank test. Categorical data were
assessed by chi-square test. P < 0.05 was considered statistically significant.
RESULTS
Of the subjects enrolled, 72 patients and 21 volunteers had recoverable BALF, and so
entered the analysis. Clinical and demographic details for patients and volunteers are
described in Table 1. Details relating to subgroups of patients are shown in the online
supplement.
The capacity of PBNs to phagocytose zymosan was significantly lower in patients than in
volunteers (Figure 1). Various strategies were employed to investigate potential mechanisms
underlying the phagocytic defect in patients. To test the hypothesis that deficient
opsonization explained the observed impairment, zymosan was incubated in serum from
patients (known to have defective PBN phagocytosis) or volunteers (known to have efficient
PBN phagocytosis), and then added to healthy PBNs from four separate donors. The rates of
phagocytosis were 61% (95% confidence interval [CI], 55–68%) and 65% (95% CI, 55–
74%) in patient- and volunteer-opsonized zymosan, respectively (P = 0.5). Further
experiments relating to opsonization are reported in the online supplement.
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To test whether a serum factor (preventing ligation of microbes to phagocytic receptors)
may explain the observed phagocytic impairment, healthy PBNs from four separate donors
were preincubated in serum from patients (known to have poor phagocytosis) and volunteers
(known to have efficient phagocytosis), and then exposed to zymosan. No significant
differences in phagocytosis were observed (P = 0.94).
PBNs from the patients and volunteers in Figure 1 were used to study correlations between
phagocytosis and expression of neutrophil phagocytic receptors (23). No significant
correlation was found for CD11b (r = −0.3, P = 0.12), activated CD11b (r = −0.2, P = 0.45),
CD32 (r = 0.3, P = 0.2), or CD64 (r = −0.34, P = 0.1). In addition, no evidence was found
for defective expression or activation of the predominant complement-mediated phagocytic
receptor CD11b (see the online supplement).
No correlation was found between phagocytosis and serum concentrations of inflammatory
cytokines including IL-6, IL-8, and TNF-α (Figures 2A–2C). In contrast, serum
concentration of C3a des-Arg demonstrated a significant inverse correlation with the
phagocytic capacity of PBNs (Figure 2D). As neutrophils have considerably more binding
sites for C5a than for C3a, leading to rapid C5a clearance from the serum, C3a is a more
reliable serum marker of complement activation and anaphylotoxin exposure (24). Serum
levels of C3a des-Arg and C5a des-Arg were significantly elevated in patients compared
with matched volunteers (see Table 1).
We therefore studied the relationship between phagocytosis and neutrophil expression of
CD88 (synonymous with C5a receptor type 1 [25]). CD88 expression is known to be down-
regulated by C5a (24). In patients and volunteers phagocytosis by PBNs correlated
significantly with expression of CD88 (Figure 3A).
On the basis of these observations the effect of C5a on neutrophil phagocytic function was
investigated further. Recombinant human C5a applied to healthy PBNs induced
simultaneous down-regulation of CD88 and impairment of phagocytosis in a dose-
dependent manner (Figure 3B), producing a similar correlation to that seen in patients. The
C5a-mediated impairment of phagocytosis could be prevented by prior treatment of PBNs
with S5/1, an antibody specifically blocking CD88 (26) (Figure 3C).
To establish whether C5a-mediated effects on PBNs were restricted to impairment of
phagocytosis, additional neutrophil functions were studied. Production of superoxide by
PBNs followed a strikingly similar pattern to phagocytosis, in that patients produced
significantly less superoxide than control subjects (Figure 4A), whereas superoxide
production showed a significant negative correlation with serum C3a des-Arg (Figure 4B)
and a positive correlation with PBN surface CD88 expression (r = 0.47, P = 0.03). Addition
of C5a to healthy PBNs resulted in significant impairment of transmigration (Figure 4C).
Similarly, addition of C5a to healthy PBNs significantly impaired the capacity to kill P.
aeruginosa, a common nosocomial pathogen (Figure 4D).
To ascertain whether the dysfunction outlined previously simply represented global
inactivity of PBNs in critically ill patients, we investigated the effects of PBNs from patients
and age/sex-matched volunteers in a model of epithelial inflammation using an epithelial
cell line (A549 cells) (22). A549 cells cocultured with PBNs released negligible amounts of
IL-6 and IL-8, irrespective of whether the PBNs came from patients or matched volunteers
(data not shown). However, when the cocultures were stimulated with LPS the patient PBNs
produced significantly greater IL-6 and IL-8 release than those from matched volunteers
(Figures 5A and 5B). The effect of LPS-stimulated PBNs on IL-6 and IL-8 release required
direct PBN–epithelial interaction, because when contact was prevented by separating the
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cells with membranes (pore size, 0.4 μm) there was significantly reduced IL-6 and IL-8
release (see insets in Figures 5A and 5B).
To further elucidate the mechanism by which C5a mediates the observed defect in
phagocytosis we examined the actions of two other agents. fMLP is a bacterial peptide that
acts via a receptor coupled to the same Gα subunit (Gαi2) as CD88 (27, 28). Incubation of
fMLP with neutrophils produced a defect in phagocytosis similar to that seen with C5a
(Figure 6A). C5a and fMLP activate several intracellular signaling pathways, including
pathways dependent on cyclic adenosine monophosphate/protein kinase A (cAMP/PKA)
(29) and PI3K (30). Both pathways have been shown to influence phagocytosis and cell
migration (31, 32). Blockade of cAMP failed to prevent the effects of C5a and fMLP on
PBN phagocytosis (see the online supplement). However, preincubation of neutrophils with
the PI3K inhibitor LY294002 blocked the effects of both C5a and fMLP on phagocytosis
(Figures 6B and 6C). A similar effect was achieved with another PI3K inhibitor,
wortmannin (data not shown).
In considering the clinical implications of our findings it could be argued that an agent
capable of reversing deficient phagocytosis would be useful. On the basis that GM-CSF has
been associated with preservation of phagocytosis in patients with sepsis (33), we postulated
that GM-CSF may reverse the phagocytic impairment described. GM-CSF conferred no
additional phagocytic capacity to healthy PBNs, but fully restored C5a-mediated impairment
of phagocytosis (Figure 7). This principle could be extended to neutrophils from patients
with suspected VAP, GM-CSF producing a 33% increase in phagocytosis (P = 0.018 by
Mann-Whitney, n = 6 separate patient neutrophil populations). Of note, the levels of GM-
CSF in patient serum and lavage were low and did not differ between patients and control
subjects (see Table 1).
The studies in PBNs and serum were extended to cells and supernatant derived from BALF,
with the aim of determining whether neutrophils accessing the alveolar compartment
function in a manner reminiscent of blood neutrophils. Impaired phagocytic function was
observed in cells derived from BALF (Figure 8A), resembling the pattern in PBNs (Figure
1). However, whereas the PBNs in Figure 1 comprised a pure population of neutrophils, the
BALF cells from patients were a mixture of alveolar macrophages (AMs) and neutrophils
(see Table 1). As neutrophils are inherently more phagocytic than AMs (compare the MV
column with the inset in Figure 8A), patient BALF cells were expected to have a phagocytic
“advantage” over volunteer BALF cells (which are almost exclusively AMs). That the
opposite trend was observed suggests a profound impairment of phagocytosis in BALF
retrieved from patients.
BALF supernatant from patients significantly reduced the capacity of healthy PBNs to
phagocytose zymosan when compared with BALF supernatant from volunteers (Figure 8B).
However, lavage fluid did not influence the expression of CD88 on healthy PBNs (Figure
8C), and application of anti-CD88 antibody S5/1 could not prevent the impairment of
phagocytosis induced by patient lavage fluid (Figure 8D). Although the levels of C3a and
C5a in lavage were elevated in patients compared with matched volunteers, the levels were
10 times lower than in serum (Table 1), and no correlation was found between lavage C3a
and lavage cell phagocytosis (r = 0.21, P = 0.2).
The impairment of neutrophil function induced by patient lavage was not limited to
phagocytosis. Patient lavage abolished transmigration of healthy PBNs (Figure 8E) and
significantly abrogated their potential to kill P. aeruginosa (Figure 8F) when compared with
lavage from matched volunteers.
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DISCUSSION
Although abnormal function of neutrophils has been observed previously in critical illness
(11, 12), our data extend these findings by proposing a central role for activated complement
in mediating dysfunction of neutrophils in the circulation. We have also identified a similar
profound impairment of neutrophil function in BALF that does not appear to be mediated by
C5a, but by an as yet unidentified factor(s).
C5a in relatively low concentrations is traditionally regarded as an inflammatory
anaphylotoxin promoting chemotaxis and activation of neutrophils (17). However, it is
increasingly recognized that C5a is overexpressed in sepsis (14), and that in this setting C5a
exerts alternative influences on neutrophil function. Thus important animal models and in
vitro experiments suggest C5a is an important mediator of neutrophil dysfunction (15–17),
acting via the major C5a receptor CD88 (25). CD88 is not directly phagocytic but is a
marker of exposure to C5a, which inhibits phagocytosis through previously undefined
mechanisms. This study provides a first clinical extension of these observations, showing
that phagocytosis correlated with CD88 expression on patient neutrophils, that C5a applied
to healthy PBNs could recapitulate the phenotype of patient PBNs, that blockade of CD88
prevented impairment of phagocytosis, that the PI3K pathway is involved in regulating
phagocytic impairment mediated by C5a, and that GM-CSF could restore phagocytosis to
levels observed before C5a exposure.
Our data cannot exclude an important influence of mediators other than C5a in driving
neutrophil dysfunction. However, we were unable to demonstrate an association between
phagocytic impairment and alterations in biological factors classically linked to
phagocytosis (e.g., expression of CD11b, CD32, and CD64). CD11b is up-regulated on
“activated” neutrophils (34) and the failure of CD11b expression to correlate with
phagocytosis suggests that the correlation observed with CD88 is not simply the result of
generalized “neutrophil activation.” CD88 down-regulation can occur after exposure to other
inflammatory mediators than C5a (35),such as IL-8 and TNF-α. However, the finding that
C3a des-Arg correlated significantly and negatively with both phagocytosis and ROS
production, when TNF-α, IL-8, and IL-6 showed no such relationship, again suggests that
impaired phagocytosis is related to anaphylotoxin generation rather than a nonspecific result
of systemic inflammation.
Although the main focus of this work was on PBN phagocytosis we demonstrated that C5a,
in concentrations relevant to critically ill patients, impaired a range of other neutrophil
functions including reactive oxygen species (ROS) generation, chemotactic migration, and
the capacity to kill the nosocomial pathogen P. aeruginosa. Thus our data are not restricted
to an effect on zymosan or to an effect on phagocytosis. Importantly, whereas neutrophils
from patients exhibit diminished function with respect to two vital antibacterial activities
(i.e., phagocytosis and ROS production), they demonstrate enhanced proinflammatory
effects toward host cells. This suggests that patient neutrophils are not in a nonspecific and
generalized “anergic state,” but in a complex dysfunctional state. The evolution of a
compensatory antiinflammatory syndrome (CARS) is well described in critical illness (36).
This concept arose largely in relation to monocyte deactivation in septic patients (37), but
other key elements of immune function are now known to be influenced in a similar way
(11, 12). The emerging consensus is that CARS and severe inflammatory response
syndrome (SIRS) are not temporally distinct phases, and may coexist and overlap within the
same patient. The finding that neutrophils may be driven into a hypofunctional state by a
classically proinflammatory mediator (C5a) supports dynamic, and potentially maladaptive,
interactions between proinflammatory molecules and neutrophils. A practical consequence
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of our findings is that CD88 may potentially serve as a marker of neutrophil dysfunction
much in the way HLA-DR expression is used in monocytes (38).
In pursuing the mechanisms by which C5a may impair neutrophil phagocytosis we were
unable to demonstrate a role for cAMP. In contrast, inhibition of PI3K abolished the effects
of C5a. This finding was perhaps surprising, given the work by Wrann and colleagues
suggesting that PI3K blockade does not rescue phagocytosis and is detrimental in a murine
model of sepsis (39). However, their work did not specifically demonstrate C5a-mediated
reduction in phagocytosis, in contrast to our findings and previous findings from the same
group (15–17, 40). It also remains plausible that responsiveness to PI3K inhibitors differs
between mice and humans. Although PI3K is generally thought to facilitate
proinflammatory functions (41), chronic PI3K activation has demonstrated
“antiinflammatory” functions (42). We hypothesize that when neutrophils are exposed to
pathological levels of C5a, as occurs in systemic inflammation and sepsis, this “overloads”
the PI3K pathways and paralyzes cellular functions such as phagocytosis. Further work is
being undertaken to elucidate the temporal interplay between C5a generation, PI3K
activation, and neutrophil function.
Given that significant levels of activated complement are generated in most critically ill
patients (14, 43), it is tempting to suggest that C5a-induced neutrophil dysfunction is
common to most ICU patients. Two important implications arise from this scenario. First,
generation of activated complement could explain the almost ubiquitous immune
impairment seen in the ICU, despite the wide variation in clinical presentations. Second,
restoration of phagocytosis may be a potential target in the design of strategies for
preventing infection in critically ill patients. In this regard anti-C5 and anti-CD88 therapies
do exist (44, 45). However, these have not yet been used in clinical trials related to critical
illness/sepsis, and of concern is the finding that CD88 knockout mice fail to clear bacteria
(46). On the basis of data presented here, GM-CSF can potentially restore C5a-mediated
neutrophil dysfunction. As endogenous levels in serum and BALF were low in our hands,
GM-CSF may be an alternative therapy worthy of further investigation. Clinical trials of
GM-CSF in nonneutropenic critical illness have been limited, and have not stratified patients
by immune phenotype (33, 47). GM-CSF could potentially have a stronger effect in
preventing nosocomial infections in patients with confirmed neutrophil dysfunction and,
encouragingly, GM-CSF–mediated preservation of neutrophil function in critically ill
patients has been demonstrated (33).
To our knowledge the phagocytic capacity of cells from the alveolar compartment has not
been systematically assessed in patients with suspected VAP. The data presented suggest
that, in contrast to neutrophils from the blood, C5a is not the mediating factor in lavage.
Levels of C3a and C5a were far lower in BALF than in serum, antibody blockade of CD88
failed to prevent the reduction in phagocytosis, and the application of lavage did not alter
CD88 expression. The implication is that phagocytic impairment is compartmentalized and
multifactorial, with contributing influences in the local inflammatory milieu and in the
circulation. It is intriguing to note that the ratio of C3a to C5a in the inflamed lung is on the
order of 2:1, in contrast to the serum, where it is 6:1, in keeping with previous literature on
this topic (48, 49). This suggests that complement activation may be differently regulated in
these two compartments, as indeed are other processes such as fibrinolysis (50).
The strength of the neutrophil impairment induced by BALF was perhaps surprising, given
that BALF is generally considered to be 100 times more dilute than epithelial lining fluid
(20). The effect of patient BALF on phagocytosis by, and transmigration of, healthy
neutrophils was particularly striking (Figures 8B and 8E, respectively). The presence of a
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potent pulmonary inhibitor(s) of neutrophil function may partly explain the high proportion,
and clinical importance, of pneumonias among HAIs in the critically ill (1).
Identification of distinct influences on neutrophil function in the blood and in the lung is
pertinent to the design of therapeutic strategies discussed earlier. Thus, restoration of
phagocytosis in PBNs may not be effective in preventing pneumonia if a local alveolar
environment capable of deactivating recruited PBNs has already evolved. It remains
unknown whether neutrophils at other sites susceptible to HAI (e.g., the urinary tract, skin
wounds, sinuses) can be deactivated by local factors or remain dependent on influences in
the blood. These considerations suggest both that a greater understanding of the
pathogenesis of HAI is required before “neutrophil restoration” therapy is realized, and that
the timing of administration of any such therapy is likely to crucial.
Extending these themes, certain cautions should be exercised in extrapolating data from our
study. The patients studied here had been mechanically ventilated in ICU for a median of 8
days and by definition already had chest X-ray infiltrates. Our study does not have the
capacity to dissect whether neutrophil dysfunction contributed to the propensity for severe
and ongoing illness, or whether it was a consequence of the specific setting (suspected VAP)
studied here. Indeed, the timing of acquisition of neutrophil dysfunction in critically ill
patients has been the focus of relatively few studies. In addition, this study was not designed
to determine the subsequent rate of HAI in our cohort of patients. Despite these caveats,
however, our patients were well characterized, satisfied strict predefined criteria for
clinically suspected VAP, and are representative of an important group of patients seen in all
ICUs. We are currently undertaking a study to investigate these issues further and to
determine whether C5a is a mediator of neutrophil dysfunction in other groups of critically
ill patients. Furthermore, although our volunteers were closely matched to the patients in age
and sex, they were not mechanically ventilated. We cannot exclude the possibility that
ventilation or underlying comorbidities may explain some of the neutrophil dysfunction
demonstrated in patients. However, this does not detract from the purpose of the study,
which was to characterize neutrophil impairment in critically ill patients.
In conclusion, critically ill patients with suspected VAP have C5a-mediated dysfunction of
peripheral blood neutrophils. A further, complement-independent impairment of neutrophil
function resides in the inflamed alveolar compartment. These findings have significant
implications for the understanding of the pathogenesis of HAI, and for the design of novel
strategies for the prevention of HAI.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Neutrophil phagocytosis is impaired in patients with suspected ventilator-associated
pneumonia (VAP) compared with matched volunteers (MVs). Phagocytosis by peripheral
blood neutrophils (PBNs) from all patients was compared with that of matched volunteers.
Data are presented as medians, interquartile ranges (box), and range (whiskers); ***P <
0.0001 by Mann-Whitney U test. Data are derived from 89 subjects (68 patients and 21
MVs); for the remaining 4 patients phagocytosis data were not available because of
insufficient PBN adherence to tissue culture plates.
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Figure 2.
Phagocytosis in peripheral blood neutrophils correlates with markers of activated
complement but not with serum IL-6, IL-8, or tumor necrosis factor (TNF)-α. (A)
Correlation between serum TNF-α and neutrophil phagocytosis (n = 79 study participants§).
(B) Correlation between serum IL-8 and neutrophil phagocytosis (n = 79 study participants).
(C) Correlation between serum IL-6 and neutrophil phagocytosis (n = 79 study participants).
(D) Correlation between serum C3a (a stable marker of complement activation) and
neutrophil phagocytosis (n = 79 study participants). All r and P values by Spearman’s
correlation. §From the n = 93 study participants in Table 1; phagocytosis data were not
available for 4, and cytokine data were not available for 10.
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Figure 3.
Effects of recombinant C5a applied ex vivo to neutrophils. (A) Correlation between
neutrophil surface C5a receptor (CD88) expression (as determined by flow cytometry) and
phagocytic capacity. Data are pooled for patients with suspected ventilator-associated
pneumonia (VAP), and matched volunteers (n = 22 consecutive study participants, i.e., an
interim analysis suggested an effect of C5a on phagocytosis, and CD88 was measured in all
consecutive subjects thereafter). r and P values by Spearman’s correlation. (B) Correlation
between phagocytosis and CD88 expression in healthy volunteer neutrophils exposed to
escalating concentrations of C5a (n = 3 peripheral blood neutrophil [PBN] donors). The
neutrophils of three separate donors were exposed to four separate doses of C5a, that is, each
symbol × is from a different donor’s neutrophils exposed to 1000 nM C5a, and so on. (C)
Effect of recombinant C5a on the phagocytic capacity of healthy human neutrophils in vitro.
Neutrophils from healthy volunteers were incubated with either S5/1 (a murine monoclonal
antibody blocking CD88) or with control antibody. Neutrophils were then exposed to C5a
and the capacity for phagocytosis of zymosan was estimated. Data are derived from
duplicates (n = 5 PBN donors) and presented as medians and interquartile range. P < 0.0001
by Kruskal-Wallis, *P < 0.05, **P < 0.01 by Dunn’s post hoc test. NS = not significant.
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Figure 4.
C5a-mediated neutrophil defects are not restricted to phagocytosis. (A) Production of
superoxide radical by neutrophils primed with 100 nM platelet-activating factor (PAF) and
stimulated with 100 nM formyl methionyl leucyl phenylalanine (fMLP). P = 0.0076 by
Mann-Whitney test. Data are derived from 16 patients and 12 matched volunteers, reflecting
consecutive subjects recruited after interim analysis suggesting an effect of C5a on
phagocytosis. (B) Correlation between PAF/fMLP-stimulated superoxide production by
neutrophils and serum C3a concentrations in patients and matched volunteers. r and P values
by Spearman’s correlation. Data are derived from 20 consecutive study participants (i.e.,
recruited after interim analysis suggesting an effect of C5a on phagocytosis). (C)
Transmigration of neutrophils across a polystyrene membrane (pore size, 3 μm) to a target
of 100 nM fMLP. Neutrophils from healthy volunteers were preincubated in control
medium, or 100 nM C5a, **P = 0.008 by Mann-Whiney test (duplicates from n = 5 healthy
peripheral blood neutrophil [PBN] donors). (D) Effect of C5a on the bactericidal capacity of
neutrophils. P. aeruginosa strain PA01 was added for 30 minutes to wells containing no cells
(left column), or to healthy neutrophils preincubated with either 100 nM C5a (middle
column) or control medium (right column). Residual bacteria were quantified and expressed
as colony-forming units (CFU) above those at t0.**P = 0.003 by Mann-Whitney (duplicates
of n = 5 healthy PBN donors).
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Figure 5.
LPS-stimulated neutrophils from critically ill patients drive increased release of
inflammatory mediators from A549 cells. (A) IL-6 release induced by LPS-stimulated
neutrophils from patients and matched volunteers (MVs). Data are expressed as a ratio of
IL-6 release by stimulated A549 cells to IL-6 release from unstimulated A549 cells. The
inset shows IL-6 release when the neutrophils were separated from A549 cells by a
Transwell (TW) membrane (pore size, 0.4 μm). Data are shown as median and interquartile
range, *P = 0.017 by Mann-Whitney U test. Data are derived from 71 study participants (57
patients and 14 MVs, i.e., all subjects from whom sufficient neutrophils and A549 cells were
available to complete the assay). The Transwell data are derived from 12 study participants.
(B) IL-8 release in the same experiments shown in (A). **P = 0.0098 by Mann-Whitney U
test.
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Figure 6.
C5a and formyl methionyl leucyl phenylalanine (fMLP) induce similar effects on
phagocytosis, which appear to be dependent on phosphoinositide 3-kinase (PI3K) signaling.
(A) The effects of C5a and fMLP on phagocytosis by healthy neutrophils. Data are
presented as median and interquartile ranges, P < 0.0001 by Kruskal-Wallis, **P < 0.01 by
Dunn’s post-hoc test (n = 6 individual peripheral blood neutrophil [PBN] donors, all
experiments performed in duplicate). (B) The effect of preincubation of healthy neutrophils
with 6.6 μM LY294002 (IC50 for PI3Kγ) before exposure to 100 nM C5a. Data are
illustrated as median and interquartile range, P = 0.0002 by Kruskal-Wallis, **P < 0.01 by
Dunn’s post-hoc test (n = 6 individual PBN donors, all experiments performed in duplicate).
(C) The effect of preincubation of healthy neutrophils with 6.6 μM LY294002 (IC50 for
PI3Kγ) before exposure to 100 nM fMLP. Data are illustrated as median and interquartile
range, P = 0.0007 by Kruskal-Wallis, **P < 0.01, by Dunn’s post-hoc test (n = 6 individual
PBN donors, all experiments performed in duplicate). NS = not significant.
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Figure 7.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) rescues phagocytic function
in neutrophils. Peripheral blood neutrophils (PBNs) from healthy volunteers were incubated
with C5a or control, and exposed to GM-CSF. The capacity for phagocytosis of zymosan
was estimated. Data are derived from duplicates (n = 5 PBN donors) and presented as means
and standard deviation. P = 0.0001 by Kruskal-Wallis, **P < 0.01 by Dunn’s post hoc test.
NS = not significant.
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Figure 8.
Lavage from patients with suspected ventilator-associated pneumonia (VAP) induces a
range of neutrophil defects in a C5a-independent manner. (A) Phagocytosis by cells
retrieved from bronchoalveolar lavage fluid (BALF) in patients and in matched volunteers
(MVs). The predominant cell in patients was the neutrophil, whereas in MVs it was the
alveolar macrophage (see Table 1). The inset shows the level of phagocytosis by the
equivalent number of neutrophils from the same MVs (making the point that phagocytosis is
more avidly performed by peripheral blood neutrophils than by alveolar macrophages). Data
are presented as medians, interquartile ranges (box), and range (whiskers), P = 0.03 by
Mann-Whitney U test. Data are derived from 44 study participants (33 patients and 11 MVs,
i.e., all subjects for whom sufficient numbers of phagocytes were available and adhered to
tissue culture plates). (B) Effect on phagocytosis of incubating healthy peripheral blood
neutrophils (PBNs) with BALF from MVs or patients with clinically suspected VAP. Data
represent duplicates from five separate healthy PBN donors and are expressed as medians,
interquartile ranges (box), and range (whiskers), ***P = 0.0001 by Mann-Whitney U test.
(C) Comparison of the effects of patients’ lavage or C5a on CD88 expression by healthy
neutrophils. Data represent duplicates from three separate healthy PBN donors and are
expressed as mean and standard deviation, P < 0.0001 by analysis of variance, **P < 0.01 by
Bonferroni’s post hoc test. (D) The effect of preincubating neutrophils with the anti-CD88
antibody S5/1 on the ability of patient lavage to induce a defect in phagocytosis in healthy
donor neutrophils. Data are shown as median and interquartile ranges of duplicates from n =
3 separate PBN donors, P < 0.001 by Kruskal-Wallis, *P < 0.05 by Dunn’s post hoc test. (E)
The effect of preincubating healthy PBNs with lavage from MVs or patients on
transmigration toward formyl methionyl leucyl phenylalanine (fMLP). Data are shown as
median and interquartile ranges of duplicates from n = 3 separate PBN donors (exposed to
lavage from one MV and six patients), P = 0.0046 by Kruskal-Wallis, **P < 0.01 by Dunn’s
post-hoc test. (F) The effect of preincubating healthy PBNs with lavage from MVs or
patients on the killing of P. aeruginosa. Data are shown as median and interquartile ranges of
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duplicates from n = 3 separate PBN donors (exposed to lavage from one MV and six
patients), **P = 0.013 by Mann-Whitney U test.
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